FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate. uri icon

Overview

abstract

  • Intrathecal methotrexate is a standard option for central nervous system-directed therapy in patients with stage III and IV diffuse large B-cell lymphoma. We present a case of a 50-year-old man with stage IV diffuse large B-cell lymphoma with widespread lymphomatous involvement including the central nervous system, who received 7 doses of intrathecal methotrexate via Ommaya catheter. Posttherapy F-FDG-PET/CT imaging demonstrated diffuse, intense intrathecal FDG avidity, without correlative findings on MR spinal imaging. FDG avidity resolved on follow-up. These PET/CT findings are most consistent with methotrexate-induced thecal inflammation, which needs to be distinguished from intrathecal malignancy.

publication date

  • December 1, 2016

Research

keywords

  • Antimetabolites, Antineoplastic
  • Inflammation
  • Methotrexate
  • Positron Emission Tomography Computed Tomography
  • Spinal Diseases

Identity

PubMed Central ID

  • PMC5583704

Scopus Document Identifier

  • 85027946418

Digital Object Identifier (DOI)

  • 10.1097/RLU.0000000000001440

PubMed ID

  • 27805919

Additional Document Info

volume

  • 41

issue

  • 12